Suppr超能文献

霍奇金病治疗后影响心脏病晚期死亡率的因素。

Factors affecting late mortality from heart disease after treatment of Hodgkin's disease.

作者信息

Hancock S L, Tucker M A, Hoppe R T

机构信息

Department of Radiation Oncology, School of Medicine, Stanford University, CA.

出版信息

JAMA. 1993 Oct 27;270(16):1949-55.

PMID:8411552
Abstract

OBJECTIVE

To assess the risk of death from heart disease after Hodgkin's disease therapy.

DESIGN

Retrospective study comparing treated patients with a matched general population.

SETTING

Referral center.

PATIENTS

A total of 2232 consecutive Hodgkin's disease patients treated from 1960 through 1991. Follow-up averaged 9.5 years.

MAIN OUTCOME MEASURES

Relative risks (RRs), the ratio of the observed to the expected cases with 95% confidence intervals (CIs), chi tests for trends, and Kaplan-Meier actuarial risks.

RESULTS

Of the 2232 patients, 88 (3.9%) died of heart disease, 55 from acute myocardial infarction and 33 from other cardiac diseases, including congestive heart failure, radiation pericarditis or pancarditis, cardiomyopathy, or valvular heart disease. The RR for cardiac death was 3.1 (CI, 2.4 to 3.7). Mediastinal radiation of 30 Gy or less (n = 385 patients) did not increase risk; above 30 Gy (n = 1830), RR was 3.5 (CI, 2.7 to 4.3). Blocking to limit cardiac exposure reduced the RR for other cardiac diseases from 5.3 (CI, 3.1 to 7.5) to 1.4 (CI, 0.6 to 2.9), but not acute myocardial infarction (RR, 3.7 vs 3.4). The RRs increased with duration after treatment (trend in acute myocardial infarction, P = .02; in other cardiac diseases, P = .004). The RR for acute myocardial infarction was highest after irradiation before 20 years of age and decreased with increasing age at treatment (P < .0001 for trend).

CONCLUSIONS

Mediastinal irradiation for Hodgkin's disease increases the risk of subsequent death from heart disease. Risk increased with high mediastinal doses, minimal protective cardiac blocking, young age at irradiation, and increasing duration of follow-up.

摘要

目的

评估霍奇金淋巴瘤治疗后死于心脏病的风险。

设计

将接受治疗的患者与匹配的普通人群进行比较的回顾性研究。

地点

转诊中心。

患者

1960年至1991年期间连续治疗的2232例霍奇金淋巴瘤患者。平均随访9.5年。

主要观察指标

相对风险(RRs)、观察病例与预期病例的比值及95%置信区间(CIs)、趋势的卡方检验以及Kaplan-Meier精算风险。

结果

在2232例患者中,88例(3.9%)死于心脏病,55例死于急性心肌梗死,33例死于其他心脏疾病,包括充血性心力衰竭、放射性心包炎或全心炎、心肌病或瓣膜性心脏病。心脏死亡的RR为3.1(CI,2.4至3.7)。30 Gy及以下的纵隔放疗(n = 385例患者)未增加风险;超过30 Gy(n = 1830),RR为3.5(CI,2.7至4.3)。限制心脏照射的屏蔽措施使其他心脏疾病的RR从5.3(CI,3.1至7.5)降至1.4(CI,0.6至2.9),但对急性心肌梗死无效(RR,3.7对3.4)。RRs随治疗后的时间延长而增加(急性心肌梗死的趋势,P = 0.02;其他心脏疾病,P = 0.004)。急性心肌梗死的RR在20岁之前接受放疗后最高,并随治疗时年龄的增加而降低(趋势P < 0.0001)。

结论

霍奇金淋巴瘤的纵隔放疗会增加随后死于心脏病的风险。风险随着高纵隔剂量、最小化的心脏保护屏蔽、放疗时的年轻年龄以及随访时间的延长而增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验